Integrated multi-omics applications in atherosclerosis provide critical theoretical and translational groundwork for developing novel diagnostics, targeted therapies, and early risk stratification tools.
Abstract Atherosclerosis is a leading global cause of disability and mortality, with a rising trend of early onset across populations. Its pathogenesis is multifactorial, encompassing multiple interconnected pathways including dyslipidemia, inflammation, and immune dysregulation. Current therapeutic strategies targeting lipoproteins are insufficient to address disease progression, and there remains an urgent unmet clinical need to further elucidate its pathogenic mechanisms, refine diagnostic approaches, and identify novel therapeutic targets. In recent years, the vigorous development of omics technology has provided help for in-depth investigation of the pathogenesis of diseases and search for new diagnosis and treatment targets. The application of multi-omics analysis has elevated atherosclerotic research to a new tier, yielding high-quality findings that further unravel atherogenic molecular mechanisms. These findings provide critical theoretical and translational groundwork for developing novel diagnostics, targeted therapies, and robust early risk stratification tools. In this review, we summarize integrated multi-omics applications in atherosclerosis, and outline novel perspectives for prospective therapeutic strategies.
Jiang et al. (Wed,) conducted a review in Atherosclerosis. Multi-omics analysis was evaluated. Integrated multi-omics applications in atherosclerosis provide critical theoretical and translational groundwork for developing novel diagnostics, targeted therapies, and early risk stratification tools.